Mar.13,2024
FIMECS Presents at the 4th Annual Targeted Protein Degradation Europe Summit
News release Download PDF
Kanagawa, Japan, 13th March 2024 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the results of its research on targeted protein degraders based on its platform technology, RaPPIDSTM, will be presented at the 4th Annual Targeted Protein Degradation Europe Summit (19-21 March 2024 in London, UK) which is a high reputational conference organized by Hanson Wade as well as their Targeted Protein Degradation Summit every autumn in Boston, USA.
Title: Exploring Novel Orally Available Degraders Screened by Phenotypic-First Approach
Presenters: Shigeyuki Mori, Rumiko Osawa, Reiko Daigaku, Yuichi Tateishi, Tomoaki Hayashi, Kazuteru Aoki, Naomi Kitamoto, Shigeru Furukubo, Toshitake Kobayashi, Kanae Gamo, Yusuke Tominari
Time and date: 14:45-17:00 (local time), Wednesday, March 20, 2024
This presentation will demonstrate the identification of degraders using novel E3 ligase by RaPPIDS™ platform technology with “Phenotypic-First Approach”, which enables highly efficient synthesis and evaluation of multiple degraders, and their optimization for orally available degraders.
For more information: https://tpd-europe.com/
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/
About RaPPIDS™
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDSTM platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.
# # #
FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
Email: info@fimecs.com